Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

13000 reported adverse events

Drugs of this class: GANCICLOVIR VALGANCICLOVIR

These side effects are most commonly reported by patients taking drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class:

#	Side effect	Count
0	CYTOMEGALOVIRUS INFECTION	1443
1	OFF LABEL USE	1304
2	DRUG INEFFECTIVE	957
3	PYREXIA	891
4	DIARRHOEA	693
5	NEUTROPENIA	676
6	LEUKOPENIA	637
7	DRUG RESISTANCE	598
8	PRODUCT USE IN UNAPPROVED INDICATION	588
9	CYTOMEGALOVIRUS VIRAEMIA	585

See all common reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

Drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	CYTOMEGALOVIRUS SYNDROME	77	0.6210
1	CYTOMEGALOVIRUS NEPHRITIS	20	0.4545
2	SMOOTH MUSCLE CELL NEOPLASM	89	0.4279
3	ENCEPHALITIS CYTOMEGALOVIRUS	98	0.4033
4	OESOPHAGOPLEURAL FISTULA	11	0.3929
5	SCOPULARIOPSIS INFECTION	12	0.3750
6	PERICARDITIS FUNGAL	15	0.3659
7	CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION	67	0.3300
8	GRANULOMATOUS ROSACEA	12	0.2857
9	FLAVOBACTERIUM INFECTION	9	0.2812

See all enriched reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]